Geneos Therapeutics: A Milestone in Cancer Immunotherapy
Geneos Therapeutics, a pioneering biotherapeutics company specializing in neoantigen-targeted personalized DNA immunotherapy, recently unveiled significant findings at the 31st Society for Neuro-Oncology (SNO) Annual Meeting held in Philadelphia. Their research highlights promising results from two patients with high-grade gliomas, showcasing the potential for sustained anti-tumor immunity and dynamic treatment strategies in clinical applications.
The Patients and Their Treatment Journey
The study presented by Dr. Tanner Johanns, an assistant professor at Washington University School of Medicine, focused on two distinct cases of glioma patients undergoing Geneos' innovative PIC (Personalized Immunotherapy for Cancer) treatment. The first patient, diagnosed with MGMT-unmethylated glioblastoma, participated in the GT-20 trial. Over five years, she received 19 doses of PIC, which encodes 38 specific neoantigens post-surgery and radiation therapy. Remarkably, despite showing some initial signs of disease progression in imaging over the years, the patient remained progression-free five years after her diagnosis, indicating a possible correlation between the immunotherapy and her sustained condition. The analysis of her blood and brain tissue revealed the emergence of functional CD8+ T cell clones, suggesting that the treatment fostered an active immune response capable of monitoring and combating her cancer.
The second patient, suffering from anaplastic astrocytoma, benefited from a compassionate use protocol applying a more dynamic form of therapy. This treatment involved the iterative redesign of her personalized therapeutic approach as more tumour-specific information became available. Her treatment included three successive generations of PIC, each with an increasing repertoire of neoantigens (30, 36, and then 43). Even after standard surgical, radiation, and chemotherapy interventions, she continued to receive PIC treatment over seven years and remained free of tumor progression for over eight years. Her brain scans, similar to the first patient, showed signs of potential progression at certain intervals, yet these issues resolved independently, corroborating the anticipation that continuous PIC treatment could effectively prevent cancer recurrences.
Exciting Implications for Personalized Cancer Treatment
Dr. Johanns remarked on the significance of these cases, noting they are the first reported instances of extended therapy using a personalized cancer vaccine in brain cancer patients. The possibility of adapting treatment plans based on ongoing assessments is groundbreaking compared to conventional methods, which often follow a static formula.
This dynamic customization presents a leading edge in cancer vaccination techniques, enhancing the potential for effective immunotherapy solutions and offering new avenues for therapies that address the rapidly evolving landscape of cancer. “It’s thrilling to see the iterative process of tumor profiling leading to successive vaccine designs,” said Niranjan Sardesai, PhD, founder and CEO of Geneos Therapeutics. The company’s GT-EPIC™ platform capitalizes on an efficient manufacturing process, allowing for real-time modifications to immunotherapy treatments based on continuous patient monitoring and the identification of new neoantigens.
The Future of Cancer Immunotherapy
The innovative advancements that Geneos Therapeutics is unveiling hold profound implications not just for glioblastoma but also for other cancer types as the PIC platform can seamlessly be expanded to target different tumors. With persistent challenges associated with glioblastoma, characterized by high resistance to traditional therapies and poor prognosis, Geneos’ approach could provide patients an invaluable advantage through targeted, personalized intervention that dynamically responds to tumor evolution.
In conclusion, Geneos Therapeutics is at the forefront of a potential revolution in cancer treatment, emphasizing the necessity of personalized and adaptable therapy systems. As their research continues to develop, the hope is to not only enhance survival rates but also foster long-term, durable responses in patients battling aggressive cancers like glioblastoma. For further updates on their groundbreaking work on personalized DNA immunotherapy, visit
Geneos Therapeutics.